Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre study.

Over time, clinicians are favouring earlier introduction of life-prolonging systemic treatment at the development of CRPC. This trend is largely driven by substantial uptake of novel androgen receptor signalling inhibitors as the preferred initial treatment for CRPC patients.